Company Filing History:
Years Active: 2011
Title: The Innovative Contributions of Ricardo Silva Rodriguez in Cancer Treatment
Introduction
Ricardo Silva Rodriguez is a notable inventor based in Ciudad de la Habana, Cuba. He has made significant strides in the field of molecular pharmacology, specifically focusing on developing novel peptides that aid in treating cancer associated with the human papilloma virus (HPV) and other epithelial tumors. His innovative work holds promise for enhancing cancer treatment methodologies.
Latest Patents
Ricardo Silva Rodriguez holds a patent for his invention titled "Peptides for the treatment of cancer associated with the human papilloma virus (HPV) and other epithelial tumors." This patent revolves around the identification of peptides designed to impede the Casein Kinase II (CKII) phosphorylation domain through direct site interaction. His invention demonstrates that eleven cyclic peptides, varying in amino acid sequences, can inhibit CKII phosphorylation in vitro while exhibiting cytotoxic effects on HPV-16 transformed cells (CaSki). Additionally, these peptides enhance the sensitivity of such cells to the cytostatic effects of interferon (IFN). His innovative peptides are also engineered to be conjugated or fused with other peptides and chemical compounds, facilitating cellular penetration.
Career Highlights
Ricardo is associated with the Centro de Ingeniería Genética y Biotecnología, where he applies his expertise to further his research in genetic engineering and biotechnology. His contributions continue to thrive within a company renowned for its focus on cutting-edge scientific discoveries.
Collaborations
Throughout his career, Ricardo has collaborated with esteemed colleagues, including Silvio Ernesto Perea Rodriguez and Osvaldo Reyes Acosta. Their collective efforts have driven advancements in cancer research and molecular pharmacology, fostering innovation within their field.
Conclusion
Ricardo Silva Rodriguez is a distinguished inventor whose contributions to peptide-based therapies represent a significant advancement in cancer treatment. His innovative approach to inhibiting CKII phosphorylation showcases the potential of molecular pharmacology in developing effective therapeutic strategies against HPV-associated cancers. As research continues, his inventions may pave the way for more effective cancer treatments, benefitting countless patients worldwide.